

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice – New Programs:** Rituximab Protocols in CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR, LYFCR); **Revised Programs:** Expanded Eligibility for Ibrutinib in the First-Line Treatment of CLL/SLL
- **Drug Update** – Medical Patient Assistance Programs Updated
- **Communities Oncology Network** – 2018-2019 OSCAR Billing Deadline
- **Benefit Drug List** – **New:** LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR, Pediatric Protocol; **Revised:** LYFCR, LYASPMED, LYSMILE, LYBEND, LYBENDR, LYCLLBEND, LYCLLFB; **Deleted:** GIEFUPRT
- **Cancer Drug Manual** – **New:** AGS-16C3F; **Revised:** Cetuximab, Interferon, Lenalidomide
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – **New:** LYCHOP, LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR, LYCVP;
- **Revised:** GIAJCAPOX, GIAJFFOX, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, GICOXB, GIEFFOXRT, GIENDO2, GIFFOXB, GIFIRINOX, GIFOLFIRI, GIFOLFOX, GIGAVCC, GIGAVCOX, GIGAVFFOXT, GIPE, GOBEP, GOCXCATB, GOEP, UGOOVBEVG, GOOVPLDC, GOTDEMACO, GOTDLR, GUBEP, GUEP, GUSCPERT, UGUTAXGEM, UGUTIP, GUVVEIP, GUVIP2, HNLACETRT, HNNAVFUFA, UHNOTLEN, LKATOATRA, LKATOP, ULKMDSA, ULKMDSL, LUAVPEM, LUSCPERT, LYABVD, LYASPMED, LYBEND, LYBENDR, LYCHLRR, LYCHOPR, LYCLLBEND, LYCLLFB, LYCODOXMR, LYCVPR, LYFCR, ULYFIBRU, LYFLUDR, ULYMIBRU, LYRITUX, LYRMTN, LYSMILE, UMYCARDEX, UMYCARLD, UMYDARBD, UMYDARLD, UMYLDR, UMYDREL, UMYLENMTN, MYMPBOR, UMYPOMDEX, SAAVGS, USANADENO, SCIMMUNE
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

Effective 01 March 2019, the BC Cancer Provincial Systemic Therapy Program has approved the following treatment programs:

Lymphoma:

All Rituximab-Containing Chemotherapy Protocols for CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR, LYFCR) – Previously, all BC Cancer rituximab-containing protocols used the rituximab dose of 375 mg/m² IV (or 1400 mg SC) given every cycle, which is the standard approved dosing for non-Hodgkin Lymphoma. However, evidence suggests that increasing rituximab dosing to 500 mg/m² IV (or 1600 mg SC) for cycle 2 and beyond is preferred in CLL/SLL patients.¹⁻³ To align with this best evidence-based practice, separate rituximab-containing chemotherapy protocols have been created for CLL/SLL to reflect this modified dosing – rituximab 375 mg/m² IV in cycle 1, followed by 500 mg/m² IV (or 1600 mg SC) in cycle 2 and beyond.¹⁻³

References:

1. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–70.
2. Hallek M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised,

EDITOR'S CHOICE

open-label, phase 3 trial. *Lancet* 2010;376:1164-74.

3. Robak T, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. *J Clin Oncol* 2010;28:1756-65.

REVISED PROGRAMS

Effective 01 March 2019, the BC Cancer Provincial Systemic Therapy Program has revised the following treatment program:

Lymphoma:

Expanded Eligibility for Ibrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (ULYFIBRU) – Ibrutinib had previously been restricted at BC Cancer for the first-line treatment of CLL/SLL patients with chromosome 17p deletion.¹ In addition to this high-risk cohort, the Lymphoma Tumour Group has now expanded the eligibility of ibrutinib to include previously untreated CLL/SLL patients who are ineligible for fludarabine therapy (FCR). FCR ineligibility is defined as patients over 65 years of age and/or a strong clinical reason that the patient is ineligible for FCR. In a phase III randomized controlled trial, ibrutinib monotherapy demonstrated improved 2-year progression-free survival (PFS) compared to bendamustine plus rituximab (87% vs. 74%, HR 0.39 95% CI 0.26-0.58).² At a median follow-up of 38 months, the median PFS was not yet reached for ibrutinib. There was no difference in median overall survival (OS) between treatment groups. Additionally, this trial included a third treatment arm involving ibrutinib plus rituximab, which demonstrated no improved PFS or OS compared to ibrutinib alone. While ibrutinib exhibited higher rates of grades 3 and 4 non-hematological toxicities (74% versus 63%), particularly atrial fibrillation, hypertension, and bleeding, bendamustine exhibited higher rates of grades 3 and 4 hematological toxicities (61% versus 41%).²

References:

1. Burger JA, Tedeschi A, Barr PM et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med* 2015;373:2425-2437.
2. Woyach JA, Ruppert AS, Heerema NA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med* 2018;379:2517-28.

DRUG UPDATE

MEDICAL PATIENT ASSISTANCE PROGRAMS UPDATED

The listing of oncology medical patient assistance programs offered by pharmaceutical companies has been updated and can be found at: www.bccancer.bc.ca/mpap.*

*Located on the BC Cancer Systemic Therapy website under Health Professionals > Systemic Therapy > Reimbursement & Forms

COMMUNITIES ONCOLOGY NETWORK

2018-2019 OSCAR BILLING DEADLINE – APRIL 4, 2019

The 2018-19 fiscal year will end on Sunday, March 31, 2019. To meet the deadlines for external reporting to the Ministry of Health, all claims for drug reimbursement for the fiscal year must be invoiced by **11:59 pm on Thursday April 4, 2019** via OSCAR (Online System for Cancer drugs Adjudication and Reimbursement). Any claims invoiced after this date will not be eligible for reimbursement. For more information, please contact oscar@bccancer.bc.ca.

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 01 March 2019, the following treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and Rituximab	LYCLLBENDR	Class I
Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and Rituximab	LYCLLCHLR	Class I
Treatment of Relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, Vincristine, Prednisone and Rituximab	LYCLLCVPR	Class I
Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and Rituximab	LYCLLFLUDR	Class I
Treatment of Recurrent/Refractory Rhabdomyosarcoma in Pediatric Patients with Cyclophosphamide, Vinorelbine and Temozolomide on the COG ARST0921 Protocol	N/A [Pediatric Protocol]	Class I

REVISED PROGRAMS

Effective 01 March 2019, subcutaneous rituximab injectable 1600 mg (RITUXAN® SC) has been added to the BC Cancer [Benefit Drug List](#) for the following protocol:

Protocol Title	Protocol Code
Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and Rituximab	LYFCR

BENEFIT DRUG LIST

Effective 01 March 2019, pegaspargase has been added to the BC Cancer [Benefit Drug List](#) for the following protocols:

Protocol Title	Protocol Code
Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma using Pegaspargase, Methotrexate and Dexamethasone	LYASPMEDX
Treatment of Natural Killer or T-Cell Lymphoma using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide	LYSMILE

Effective 01 March 2019, bendamustine-based protocols have been changed to Class I status on the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code
Treatment of Non-Hodgkin Lymphoma with Bendamustine	LYBEND
Treatment of Non-Hodgkin Lymphoma with Bendamustine and Rituximab	LYBENDR
Treatment of Relapsed Chronic Lymphocytic Leukemia with Bendamustine	LYCLLBEND
Treatment of Previously Untreated Chronic Lymphocytic Leukemia with Bendamustine and Rituximab	LYCLLFBR

DELETED PROGRAMS

Effective 01 March 2019, the following treatment program has been deleted from the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code
Combined Modality Therapy for Locally Advanced Esophageal Cancer using Fluorouracil and Cisplatin	GIEFUPRT

NEW MONOGRAPHS AND PATIENT HANDOUTS

The following drug is NOT a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). Its corresponding Interim Monograph is made available for reference only. All BC Cancer drug monographs and patient handouts can be accessed on the [Cancer Drug Manual](#) Drug Index.

AGS-16C3F Interim Monograph has been developed. AGS-16C3F is an antibody-drug conjugate comprised of a fully human monoclonal antibody conjugated to a microtubule disrupting agent. Outside of clinical trials, AGS-16C3F is only available through the Health Canada Special Access Programme (SAP). The usual dosing is 1.8 mg/kg IV given in a three-weekly schedule. AGS-16C3F has now been added to the **Chemotherapy Preparation and Stability Chart** and the **Hazardous Drug List**.

Highlights from this document:

- Visual and ocular disorders are reported in approximately 85% of patients. The most frequently reported events include dry eyes, blurry vision and keratitis. However, diplopia, reduced acuity, photophobia, eye pain/irritation/swelling, and other ocular toxicities have also been reported.
- Infusion reactions are reported in up to 24% of patients. Reactions are mainly grades 1 to 2 in severity and may include pruritus, flushing, upper body rash or fever. Following a reaction, suitable premedication should be used prior to each subsequent infusion.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs, Patient Handouts and Chemotherapy Preparation and Stability Chart (CPSC) are listed below:

Cetuximab CPSC:

- Update manufacturer from BMS to Eli Lilly

Interferon Monograph and CPSC:

- *Supply and Storage, CPSC* – deleted multidose pens and 18 MU vial of lyophilized powder as they are no longer available in Canada

Lenalidomide Monograph and Patient Handout:

- *Side Effects* – added progressive multifocal encephalopathy (PML)
- *Dosing* – updated references and added BC Cancer protocols
- *Patient Handout* – added PML to bullets in Emergency section

LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
LYCHOP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine and Prednisone
LYCLLBENDR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and Rituximab
LYCLLCHLR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and Rituximab
LYCLLCVPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, Vincristine, Prednisone and Rituximab
LYCLLFLUDR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and Rituximab
LYCVP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIAJCAPOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility, Tests, Treatment, Contact Information, Side Effects management updated</i>	Adjuvant combination chemotherapy for stage III and stage IIB colon cancer using oxaliplatin and capecitabine
GIAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility, Tests, Treatment, Contact Information, Side Effects management updated</i>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin, Fluorouracil, and Leucovorin
GIAVTZCAP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name, Eligibility, Contact Physician updated</i>	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GICAPIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institution name and Logo, Eligibility, Tests, Treatment, Contact Information updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI
GICAPOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institution name and Logo, Eligibility, Tests, Treatment, Contact Information, Side Effects management updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, and Capecitabine
GICART	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy
GICOXB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine
GIEFFOXRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institution name and Logo, Eligibility, Treatment, Contact Information updated</i>	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy
GIENDO2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and Doxorubicin
GIFFOXB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Bevacizumab
GIFIRINOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, Tests, Treatment, Contact Information updated</i>	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin
GIFOLFIRI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility, Tests, Treatment, Contact Information, Side Effects management updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Leucovorin
GIFOLFOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, Treatment, Contact Information updated</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin
GIGAVCC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institution name and Logo, Title, Eligibility, Treatment updated</i>	Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, or Esophageal Squamous Cell Carcinoma using Cisplatin and Capecitabine

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIGAVCOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility updated	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, and Oxaliplatin
GIGAVFFOXT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Minor typo corrected	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab
GIPE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Institution name, Tests, Carboplatin Dosing updated	Palliative Therapy of Neuroendocrine Tumours using Cisplatin and Etoposide
GOBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Institution name updated, Test clarified	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer using Bleomycin, Etoposide, and Cisplatin
GOCXCATB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Institution name updated, Test updated	Treatment of Metastatic or Recurrent Cancer of the Cervix with Bevacizumab, Carboplatin and Paclitaxel
GOEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Institution name updated, Test updated	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer using Cisplatin and Etoposide
UGOOVBEVG	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Tests updated	Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine
GOOVLDC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Institution name updated, Test updated, Hypersensitivity information added	Treatment of Epithelial Ovarian Cancer Relapsing After Primary Treatment using Doxorubicin Pegylated Liposomal (CAELYX) and Carboplatin
GOTDEMACO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Test updated	Therapy for High Risk Gestational Trophoblastic Neoplasia using Etoposide, Methotrexate, Leucovorin (Folinic Acid), Dactinomycin, Cyclophosphamide and Vincristine
GOTDLR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Test clarified	Therapy for Low Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate
GUBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Test clarified	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide, Cisplatin
GUPE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Institution name updated, Test clarified	Etoposide-Cisplatin Protocol for Germ Cell Cancers
GUSCPERT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Cisplatin infusion time clarified	Therapy of Genitourinary Small Cell Tumors with a Platinum and Etoposide with Radiation

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPO	Patient Handout	Changes	Protocol Title
UGUTAXGEM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Test clarified</i>	Palliative Therapy for Germ Cell Cancers using Paclitaxel and Gemcitabine
UGUTIP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Test clarified</i>	Advanced Therapy for Relapsed Testicular Germ Cell Cancer using Paclitaxel, Ifosfamide and Cisplatin
GUVEIP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Test clarified</i>	Consolidation and Salvage Treatment for Germ Cell Cancer using Vinblastine, Cisplatin, Ifosfamide and Mesna
GUVIP2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Test clarified</i>	Consolidation and Salvage Therapy for Nonseminoma using Etoposide, Cisplatin, Ifosfamide and Mesna
HNLACERT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Magnesium supplement clarified</i>	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
HNAVFUFA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Weekly treatment clarified</i>	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Fluorouracil and Leucovorin
UHNOTLEN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dispensed quantity clarified</i>	Therapy for Locally Recurrent or Metastatic, RAI-Refractory Differentiated Thyroid Cancer using Lenvatinib
LKATOATRA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name, Tests, Premedication, Support Medications updated</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)
LKATOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institution name, Tests, Premedication, Support Medications updated</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and Daunorubicin
ULKMSA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy of Myelodysplastic Syndrome using Azacitidine
ULKMSL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose Modification clarified</i>	Therapy of Myelodysplastic Syndrome using Lenalidomide
LUAVPEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration updated</i>	Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer with Pemetrexed
LUSCPERT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institution name updated, Cisplatin infusion time clarified</i>	Therapy of Limited Stage Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LYABVD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Tests and Treatment cycles updated</i>	Treatment of Hodgkin Lymphoma with Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine
LYASPMEDX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title, Tests, Supportive Medications, and Treatment drugs updated</i>	Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma using Pegaspargase, Methotrexate and Dexamethasone
LYBEND	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, Protocol Code and Institutional name updated</i>	Treatment of Non-Hodgkin Lymphoma with Bendamustine
LYBENDR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, Protocol Code and Institutional name updated</i>	Treatment of Non-Hodgkin Lymphoma with Bendamustine and Rituximab
LYCHLRR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Treatment of Indolent B-Cell Lymphoma and Chronic Lymphocytic Leukemia with Chlorambucil and Rituximab
LYCHOPR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment cycles clarified</i>	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab
LYCLLBEND	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and Protocol Code updated</i>	Treatment of Relapsed Chronic Lymphocytic Leukemia with Bendamustine
LYCLLFBR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility, Protocol Code, Bendamustine Dose and Contact Physician updated</i>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia with Bendamustine and Rituximab
LYCODOXMR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Tests and Cyclophosphamide infusion time clarified</i>	Treatment of Burkitt Lymphoma and Leukemia with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab
LYCVPR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone and Rituximab
LYFCR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Rituximab dosing, Eligibility, Reference and note on renal function updated</i>	Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and Rituximab

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPO	Patient Handout	Changes	Protocol Title
ULYFIBRU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility and Title updated	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Ibrutinib
LYFLUDR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility updated	Treatment Relapsed Indolent Lymphoma with Fludarabine and Rituximab
ULYMIBRU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility updated	Treatment of Relapsed/Refractory Mantle-Cell Lymphoma using Ibrutinib
LYRITUX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Minor typo corrected	Treatment of Lymphoma with Single Agent Rituximab
LYRMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility updated	Maintenance Rituximab for Indolent Lymphoma
LYSMILE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Title, Tests, Supportive Medications, and Treatment drugs updated	Treatment of Natural Killer or T-Cell Lymphoma using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide
UMYCARDEX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Pre-treatment metrics updated	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone with or without Cyclophosphamide
UMYCARLD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Pre-treatment metrics updated	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone
UMYDARBD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eligibility, Tests and Dexamethasone dose clarified, minor typo corrected	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide
UMYDARLD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eligibility, Tests, Treatment section and Dexamethasone dose clarified, minor typo corrected	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone
UMYLDF	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Abbreviations corrected	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-dose Dexamethasone
UMYLDREL	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Abbreviations corrected	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone
UMYLENMTN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Abbreviations corrected	Maintenance Therapy of Multiple Myeloma using Lenalidomide

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
MYMPBOR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dexamethasone option added</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan
UMYPOMDEX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Abbreviations corrected</i>	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone
SAAVGS	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Second Line Treatment of Advanced C-Kit Positive Gastrointestinal Stromal Cell Tumours after Imatinib using Sunitinib
USANADENO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institution name updated, Test clarified</i>	Denosumab for Neoadjuvant Use in Patients with Non-Metastatic Operable Giant Cell Tumour of the Bone
SCIMMUNE	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Alert card added</i>	Management of Immune-Mediated Adverse Reactions to Checkpoint Inhibitors Immunotherapy

WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Provincial Professional Practice Nursing			BCCancerPPNAdmin@ehcnet.phsa.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820		rxchemocert@bccancer.bc.ca
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Caroline Lohrisch, MD

Ava Hatcher, RN, MN, CON(c)
 Naren Bollipalli, BSc(Pharm)